AnthonyW.TolcherMD

Oncology • San Antonio, TX

Breast Cancer, Sarcoma

Director of Clinical Research at START; Associate Editor of The Journal of New Anticancer Agents

Join to view full profile

Dr. Tolcher is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tolcher's full profile

Already have an account?

Office
2829 Babcock Rd
Ste 300
San Antonio, TX 78229
Phone+1 210-580-9500

Fax+1 210-568-4397

Education & Training

University of British ColumbiaClass of 1986

Certifications & Licensure

TX State Medical License 1998 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

Chemotherapy in Treating Patients With Advanced Solid Tumors Start of enrollment: 1998 Jul 01
Completed
Phase 1
Chemotherapy in Treating Patients With Advanced Solid Tumors Start of enrollment: 1998 Oct 01
Completed
Phase 1
Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer Start of enrollment: 2000 Jun 01
Completed
Phase 1, Phase 2
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Start of enrollment: 2000 Jun 01
Completed
Phase 1
Erlotinib in Treating Patients With Advanced Kidney Cancer Start of enrollment: 2002 Jun 01
Completed
Phase 2
Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer Start of enrollment: 2002 Oct 01
Completed
Phase 1, Phase 2
Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease Start of enrollment: 2006 Jul 01
Completed
Phase 1
Safety Study of CALAA-01 to Treat Solid Tumor Cancers Start of enrollment: 2008 May 01
Terminated
Phase 1
A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors Start of enrollment: 2010 Dec 01
Completed
Phase 1
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies Start of enrollment: 2013 Mar 01
Completed
Phase 1, Phase 2
Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma Start of enrollment: 2013 Jul 01
Terminated
Phase 1
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma Start of enrollment: 2014 Apr 01
Terminated
Phase 1
Phase 1 of EC1169 In Patients With Recurrent MCRPC Start of enrollment: 2014 May 01
Completed
Phase 1
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer Start of enrollment: 2015 Sep 01
Completed
Phase 1
Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors Start of enrollment: 2017 Nov 28
Active, not recruiting
Phase 1
A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Patients With Advanced Cancer Start of enrollment: 2018 Oct 16
Completed
Phase 1
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers Start of enrollment: 2019 Apr 10
Completed
Phase 1
Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A Start of enrollment: 2019 May 01
Recruiting
Phase 1
Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2021 Jun 11
Terminated
Phase 1
Roles: Contact
A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors Start of enrollment: 2022 Aug 25
Recruiting
Phase 1, Phase 2
Roles: Contact
A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors Start of enrollment: 2018 Aug 29
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
A Study of Injection HB0025 in Patients With Advanced Solid Tumors Start of enrollment: 2021 Mar 10
Recruiting
Phase 1
Roles: Contact
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) Start of enrollment: 2019 Dec 20
Active, not recruiting
Phase 1
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

30 citations
Phase I and Pharmacokinetic Study of NSC 655649, a Rebeccamycin Analog With Topoisomerase Inhibitory Properties
Anthony W. Tolcher, S. Gail Eckhardt, John G. Kuhn, Lisa A. Hammond, Geoffrey R. Weiss
Journal of Clinical Oncology. 2001-06-01
1729 citations
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Mark E. Davis, Jonathan E. Zuckerman, Chung Hang Jonathan Choi, David Seligson, Anthony W. Tolcher
Nature. 2010-04-15
241 citations
Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA
Jonathan E. Zuckerman, Ismael Gritli, Anthony W. Tolcher, Jeremy D. Heidel, Dean Lim
Proceedings of the National Academy of Sciences of the United States of America. 2014-08-05

Lectures

An open label, multicenter, phase 1b/2 study of rebastinib (DCCâ€‘2036) in combination with carboplatin to assess safety, tolerability, and pharmacokinetics in patient...
2019 ASCO Annual Meeting - 6/1/2019
Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Vial, Working with Top Phase I Oncology SitesApril 19th, 2023
Weekly Quick Hits (Greater Philadelphia) – Week of February 6, 2023February 9th, 2023
Teon Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate TT-816, a Novel Oral Immune Response Modifier, in Combination with KEYTRUDA® (Pembrolizumab)January 18th, 2023
Join now to see all

Grant Support

PH I Study Of EGFR And HER2 Blockade W/ OSI-774, Trastuzumab And PaclitaxelNational Center For Research Resources2006–2007
Phase I Clinical Trials Of Anti-Cancer AgentsNational Cancer Institute2004–2006
PH II PK And Biologic Correlative Study Of OSI-774 In PTS W/ Adv Renal Cell CarcNational Center For Research Resources2005
PH I Study Of EGFR And HER2 Blockade W OSI-774, Trastuzumab And PaclitaxelNational Center For Research Resources2005
Phase I/II Study Of Oblimersen Sodium With LeucovorinNational Center For Research Resources2004
PH II Pharmakokinetic/Biologic Study Of OSI-774 In RCCNational Center For Research Resources2004
Trial Of RPR 116258a--1 HR IV Infusion In Solid TumorsNational Center For Research Resources2000–2002
Pharmacokinetics/Safety Of INGN 201 In Advanced TumorsNational Center For Research Resources2000–2002
Pharmacokinetics Of Sr45023a 7 Day Administration CycleNational Center For Research Resources2000–2002
Pharmacokinetics Of FB 642 In Patients With Advanced TumNational Center For Research Resources2000–2002
Phase I Study Of Cyclic Oral Administration Of Sch61365 (21 Of 28 Days)National Center For Research Resources1999–2002